Clinical trials: Mask
Macular Edema, Diabetic Macular Edema
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
To evaluate the safety and tolerability of LKA651 in patients with macular edema from diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or retinal vein occlusions (RVO)
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
- Trial name
- NCT02867735
- Testing
- LKA651
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Dry Age-related Macular Degeneration
QA102 Phase II Study in Subjects With Dry AMD
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA)…
- Trial name
- AMEND (NCT05536752)
- Testing
- QA102
- Where
- 29 sites in United States
- Volunteers
- 150 people
- Sponsor
- Smilebiotek Zhuhai Limited
Macular Degeneration, Choroidal Neovascularization
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
This study evaluated the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab monotherapy and the durability of response observed in…
- Trial name
- NCT00436553
- Testing
- Verteporfin Photodynamic Therapy, Ranibizumab
- Where
- 43 sites in United States, Canada
- Volunteers
- 321 people
- Sponsor
- Novartis
Age-Related Macular Degeneration
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy…
- Trial name
- NCT05230537
- Testing
- Iptacopan (LNP023)
- Where
- 28 sites in United States, China and 2 more
- Volunteers
- 168 people
- Sponsor
- Novartis Pharmaceuticals
Open-angle Glaucoma, Ocular Hypertension
Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the IOP-lowering efficacy of a combination of Travoprost / Timolol maleate, dosed in the morning or in the evening, in patients with open-angle glaucoma or ocular hypertension, who have an…
- Trial name
- NCT00759239
- Testing
- Travoprost 0.004% / Timolol maleate 0.5%
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Alcon Research
Adenoviral Conjunctivitis
OKG-0301 for the Treatment of Acute Adenoviral Conjunctivitis
Acute adenoviral conjunctivitis is a highly contagious, widespread endemic disease associated with frequent outbreaks, significant patient discomfort, lost productivity, and in some cases permanent visual compromise from…
- Trial name
- RUBY (NCT03856645)
- Testing
- OKG-0301
- Where
- 6 sites in Australia
- Volunteers
- 219 people
- Sponsor
- Okogen
Dry Eye Syndrome
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT02597803
- Testing
- RGN-259
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- ReGenTree, LLC
Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD)
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4…
- Conditions
- Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
- Trial name
- NCT06664502
- Testing
- EYE201
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 38 people
- Sponsor
- EyeBiotech Ltd.
Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to…
- Trial name
- Brilliance (NCT01922102)
- Testing
- Ranibizumab 0.5mg, Ranibizumab 0.5 mg, Verteporfin PDT
- Where
- 47 sites in China, Hong Kong and 4 more
- Volunteers
- 457 people
- Sponsor
- Novartis Pharmaceuticals
Cataract Extraction
Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.
This is an exploratory study to determine the safety and clinical benefit of OMS302 Injection in subjects undergoing Cataract Extraction with Lens Replacement (CELR) using a coaxial phacoemulsification process.
- Trial name
- NCT00721695
- Testing
- OMS302, OMS302-PE, Vehicle
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Omeros Corporation
Pathological Myopia
Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
This study is designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to…
- Trial name
- NCT01217944
- Testing
- Ranibizumab, Verteporfin PDT
- Where
- 74 sites in Austria, Canada and 18 more
- Volunteers
- 277 people
- Sponsor
- Novartis Pharmaceuticals
Obstructive Sleep Apnea
Evaluation of the F&P Toffee Nasal Pillows Mask, US, 2022
The purpose of this clinical investigation is to evaluate the performance and safety of the F\&P Toffee nasal pillows mask in a home environment.
- Trial name
- NCT05573763
- Testing
- F&P Toffee
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fisher and Paykel Healthcare
Sleep Disordered Breathing, Obstructive Sleep Apnea
The Evaluation of an Alternative Sizing Model in Comparison of a Conventional Sizing Model for Full Face Masks in the Treatment of OSA in Terms of Performance and Comfort
The investigation is a prospective non-blinded and semi-randomized clinical investigation. The investigation is designed to assess the alternative sizing model which the trial mask concept is based on and how it compares to a…
- Trial name
- NCT02851628
- Testing
- Alternative sizing model based trial mask, Prototype Full Face Mask
- Where
- 4 sites in New Zealand
- Volunteers
- 20 people
- Sponsor
- Fisher and Paykel Healthcare
Retinal Disease
SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)
This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
- Trial name
- RELIEF (NCT05747430)
- Testing
- IRX-101, Providone-Iodine
- Where
- 7 sites in United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- iRenix Medical, Inc.
Dry Eye
LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease
The purpose of this study is to evaluate the efficacy of LME636 compared to vehicle in the reduction of ocular symptoms and to evaluate the safety and tolerability of LME636, when administered topically for up to 42 days, in…
- Trial name
- NCT02365519
- Testing
- LME636 ophthalmic solution, LME636 Vehicle
- Volunteers
- 514 people
- Sponsor
- Alcon, a Novartis Company
Keratoconjunctivitis Sicca, Dry Eye Disease
Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in the treatment of Dry Eye.
- Trial name
- OPUS-1 (NCT01421498)
- Testing
- Lifitegrast
- Where
- 13 sites in United States
- Volunteers
- 588 people
- Sponsor
- Shire
Macular Degeneration
Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)
The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.
- Trial name
- NCT00087763
- Testing
- Macugen ™ (pegaptanib sodium injection)
- Volunteers
- 135 people
- Sponsor
- Eyetech Pharmaceuticals
Ischaemic Central Retinal Vein Occlusion, Neovascular Glaucoma
Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG
A prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the…
- Trial name
- STRONG (NCT02947867)
- Testing
- aganirsen
- Volunteers
- 333 people
- Sponsor
- Gene Signal SAS
Musculoskeletal Pain
Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine and Caffeine in Osteomuscular Treatment
The purpose of this study is to evaluate the safety and efficacy of an association with one anti-inflammatory and one muscle relaxant plus caffeine compared to one anti-inflammatory plus caffeine in the treatment of osteomuscular…
- Trial name
- NCT02862977
- Testing
- ketoprofen and cyclobenzaprine association with caffeine, Cyclobenzaprine with caffeine
- Where
- 6 sites in Brazil
- Volunteers
- 414 people
- Sponsor
- EMS
Retinitis Pigmentosa (RP), Usher Syndrome
24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001.
- Trial name
- NCT07290530
- Testing
- N-acetylcysteine amide
- Volunteers
- 80 people
- Sponsor
- Nacuity Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.